About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Rheumatology Research Group (GRR) is focused on translational research in immunity-mediated inflammatory diseases (IMIDA), mainly in the area of rheumatology. The GRR is a multidisciplinary group made up of clinical specialists, biologists, bioinformaticians and laboratory technicians. The different research lines of the GRR emphasize the use of high-performance technologies for the study at the cellular and molecular level of the immununopathology of IMIDA, mainly chronic inflammatory arthritis and autoimmune systemic diseases.
At the clinical level, we have developed lines of research in very diverse areas of rheumatology, including chronic inflammatory arthritis (rheumatoid arthritis, spondyloarthropathies), systemic autoimmune diseases (lupus, myositis, Sjögren's syndrome), the study of musculoskeletal imaging, pediatric rheumatology (juvenile idiopathic arthritis, autoimmune systemic diseases, autoinflammatory syndromes), central sensitization syndromes and the study of bone metabolism. One of the main objectives of the GRR is the coordination of basic and clinical research to accelerate the transfer of knowledge to clinical practice and thus improve the quality of life of patients.
PMID: 35702721 Journal: MEDICINA CLINICA Year: 2022 Reference: Med Clin (Engl Ed). 2022 May 27;158(10):466-471. doi: 10.1016/j.medcle.2021.05.021. Epub 2022 Jun 9. Impact factor: 1.725 Publication type: Paper in international publication Authors: Domingo-Baldrich, Eva, Michelena, Xabier, Meza, Beatriz, Garcia-Vives, Eloi, Gil-Vila, Albert, Sarrapio-Lorenzo, Javier, Romero-Ruperto, Sheila, Sanpedro-Jimenez, Francesc, Arranz-Betegon, Maria, Fernandez-Codina, Andreu et al. DOI: 10.1016/j.medcle.2021.05.021
PMID: 34256936 Journal: MEDICINA CLINICA Year: 2022 Reference: Med Clin (Barc). 2022 May 27;158(10):466-471. doi: 10.1016/j.medcli.2021.05.013. Epub 2021 Jun 16. Impact factor: 1.725 Publication type: Paper in national publication Authors: Sempere-Gonzalez, Abiu, Llaneras-Artigues, Jordi, Pinal-Fernandez, Iago, Canas-Ruano, Esperanza, Orozco-Galvez, Olimpia, Domingo-Baldrich, Eva, Michelena, Xabier, Meza, Beatriz, Garcia-Vives, Eloi, Gil-Vila, Albert et al. DOI: 10.1016/j.medcli.2021.05.013
PMID: 35293988 Journal: RHEUMATOLOGY Year: 2022 Reference: Rheumatology (Oxford). 2022 Mar 16. pii: 6549521. doi: 10.1093/rheumatology/keac162. Impact factor: 7.58 Publication type: Paper in international publication Authors: Di Matteo, Andrea, Cipolletta, Edoardo, Destro Castaniti, Giulia Maria, Smerilli, Gianluca, Airoldi, Carla, Aydin, Sibel Zehra, Becciolini, Andrea, Bonfiglioli, Karina, Bruns, Alessandra, Carrara, Greta et al. DOI: 10.1093/rheumatology/keac162
PMID: 34893470 Journal: ANNALS OF THE RHEUMATIC DISEASES Year: 2022 Reference: Ann Rheum Dis. 2022 Apr;81(4):490-495. doi: 10.1136/annrheumdis-2021-220964. Epub 2021 Dec 10. Impact factor: 19.103 Publication type: Paper in international publication Authors: Dubash, Sayam, Alabas, Oras A, Michelena, Xabier, Wakefield, Richard J, Helliwell, Philip S, Emery, Paul, McGonagle, Dennis G, Tan, Ai Lyn, Marzo-Ortega, Helena, Garcia-Montoya, Leticia et al. DOI: 10.1136/annrheumdis-2021-220964
Funded by the European Union, this project coordinated by the Vall d'Hebron Research Institute (VHIR) seeks to develop more effective therapies by creating new combinations of existing drugs
The head of the Rheumatology Service at Vall d'Hebron University Hospital and of the Rheumatology research group at VHIR is a highly accomplished rheumatologist with a distinguished career in the field.
It is the first international multi-centre clinical trial to analyse the safety and effect of this treatment for an autoimmune disease.
